Major Clinical Trial Compares Three Caffeine Regimens for Preterm Infants

University of Melbourne investigators are launching a randomized comparison of three caffeine citrate regimens in preterm babies, Mirage News reports, addressing one of the few dosing questions that has persisted in neonatal intensive care despite decades of routine clinical exposure.

The BabyCCINO (Caffeine Citrate to Improve Neonatal Outcomes) trial, scheduled to begin on October 22, will enroll very preterm infants (born more than eight weeks early) across neonatal intensive care units in Australia, New Zealand, and the United Kingdom. According to Mirage News, the study is led by Professor Brett Manley, a neonatologist and Director of Newborn Research at Melbourne's Mercy Hospital for Women and Professor in the Department of Obstetrics, Gynaecology and Newborn Health at the University of Melbourne. The protocol is funded by a $3,014,066 grant from the National Health and Medical Research Council, alongside a portion of a Medical Research Future Fund award and philanthropic contributions from Running for Premature Babies, an organization founded by Sophie Smith OAM after the loss of her prematurely born triplet sons.

Unresolved dosing after two decades of use

Caffeine citrate is one of the most widely administered medications in neonatal intensive care, used to stimulate breathing and treat apnoea of prematurity, a condition in which very preterm infants temporarily cease breathing. Despite that volume of use, dose selection and timing vary across Australian and international centers. "Preterm babies receive caffeine every day, but we still don't know which dose delivers the best outcomes," Professor Manley said, per Mirage News. The three-arm comparison is designed, in the investigators' stated terms, to produce evidence-based guidance to standardize that practice.

The protocol explicitly builds on the landmark Caffeine for Apnoea of Prematurity (CAP) trial, published roughly twenty years ago, which Mirage News describes as having established the clinical utility of caffeine in this population. CAP closed one set of efficacy questions; BabyCCINO targets the residual question of dose.

Parallel neonatal evidence and what trial design controls

A separate randomized controlled trial published in Nature offers a methodological comparator for evaluating interventions on very preterm cohorts. Conducted between April 2018 and June 2019 in a tertiary NICU, the study assigned 85 infants under 31 weeks gestation or weighing ≤1500 grams to either single-family rooms (SFR, n=43) or an open-bay unit (OB, n=42). The primary composite outcome, death or neurodevelopmental impairment at 36 months corrected age, did not differ between groups (40.5% SFR vs. 47.4% OB, p = 0.644). Mortality, a pre-specified secondary outcome, was lower in the SFR arm (1/41, 2.4%) than in the OB arm (8/42, 19.0%), p = 0.029. The trial was registered with ClinicalTrials.gov as NCT03867669 on 6 March 2019.

The pattern is instructive: a null primary endpoint with a positive secondary signal demands cautious interpretation, and post-hoc inference from such patterns has historically weakened confidence in earlier neonatal pharmacotherapy studies. BabyCCINO's interpretability will rest on equivalent clarity around its pre-specified primary endpoint and analysis plan, alongside the multi-jurisdictional site coverage Mirage News describes.

Bioethical weight of variability in a non-consenting population

For audiences tracking pediatric pharmacology and preventive protocols in non-consenting populations, the trial's significance is not caffeine-specific. Where dose selection for a widely used agent varies across institutions, exposure is not standardized, and downstream long-term safety surveillance becomes difficult to interpret. Mirage News reports that the project has secured national funding and near-complete NICU participation across Australia and New Zealand, plus multiple UK sites. The architecture of parental consent for infants born more than eight weeks early, the pre-specified stopping criteria, and the granularity of adverse-event reporting will determine whether the resulting estimate is generalizable across the dosing practices BabyCCINO aims to replace.

According to Mirage News, Professor Manley indicated that findings are expected to establish evidence-based dosing guidance and help standardize neonatal intensive care practice globally. Whether the protocol delivers on that stated objective, or whether its primary endpoint drifts toward secondary signals of the type flagged by recent NICU trials, remains an open empirical question pending enrollment and follow-up.